RCKT · NASDAQ
Rocket Pharmaceuticals (RCKT) Stock Price & Fundamentals
Rocket Pharmaceuticals (RCKT) closed at $522.92 on Oct 9, 2026, up 1.62% from the previous close of $514.57.
Share price, past year
1Y +39.74%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $522.92 |
| Sep 30, 2026 | $525.49 |
| Aug 31, 2026 | $546.47 |
| Jul 31, 2026 | $519.90 |
| Jun 30, 2026 | $514.98 |
| May 29, 2026 | $487.89 |
| Apr 30, 2026 | $487.92 |
| Mar 31, 2026 | $471.77 |
| Feb 27, 2026 | $428.15 |
| Jan 30, 2026 | $428.08 |
| Dec 31, 2025 | $419.88 |
| Nov 28, 2025 | $403.10 |
| Oct 31, 2025 | $395.06 |
Key statistics
- Market cap
- $57.28B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.17
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$17.25M
- Shares outstanding
- 109.5M
- Dividend yield
- —
- 52-week range
- $371.69 – $552.24
Rocket Pharmaceuticals's market cap is $57.28B, based on a share price of $522.92 and 109.5M shares outstanding as of Jun 30, 2026.
Financials
Rocket Pharmaceuticals reported revenue of $0.00 for fiscal 2025.
Rocket Pharmaceuticals reported a net loss of $223.12M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$223.12M | — | −$2.01 | −$190.45M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$258.75M | — | −$2.73 | −$215.59M |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$245.60M | — | −$2.92 | −$211.35M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$221.86M | — | −$3.26 | −$186.50M |
| FY2021ended Dec 31, 2021 | $0.00 | — | −$169.07M | — | −$2.67 | −$128.78M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$139.70M | — | −$2.52 | −$95.25M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$77.27M | — | −$1.58 | −$87.93M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$74.52M | — | −$1.89 | −$55.24M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$19.58M | — | −$2.88 | −$16.72M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$7.57M | — | −$1.11 | −$5.84M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | $123.21M | $1.08 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$47.59M | −$0.42 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$42.54M | −$0.38 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$50.33M | −$0.45 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$68.92M | −$0.62 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$61.33M | −$0.56 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$60.33M | −$0.62 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$66.72M | −$0.71 |
Company profile
- Name
- Rocket Pharmaceuticals, Inc.
- Ticker
- RCKT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 350 Fifth Avenue, Suite 7530, New York, NY 10118
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001281895
Recent SEC filings
- Oct 6, 2026
- Sep 15, 2026
- Aug 27, 2026
- Aug 10, 2026
- Aug 10, 2026
- Aug 3, 2026
- Jun 30, 2026
- Jun 12, 2026
Frequently asked questions
What is Rocket Pharmaceuticals's stock price?
Rocket Pharmaceuticals (RCKT) closed at $522.92 on Oct 9, 2026, up 1.62% from the previous close of $514.57.
What is Rocket Pharmaceuticals's market cap?
Rocket Pharmaceuticals's market cap is $57.28B, based on a share price of $522.92 and 109.5M shares outstanding as of Jun 30, 2026.
How much revenue does Rocket Pharmaceuticals make?
Rocket Pharmaceuticals reported revenue of $0.00 for fiscal 2025.
Does Rocket Pharmaceuticals pay a dividend?
Rocket Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Rocket Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures